The currently dominant method for the purification and separation of therapeutic proteins (e.g., monoclonal antibodies, mRNA) is packed-bed chromatography. However, as the production demand for these biopharmaceuticals will continue to increase, the already expensive operating costs of chromatography will rise proportionally. Therefore, the Myerson group focuses on the underlying research for the development of solid-based purification and separation processes via continuous protein crystallization and precipitation.
